Agency officials say the case targets large pharmaceutical health insurance administrators, who allegedly favor more expensive insulin products and force patients to pay more.
Agency officials say the case targets large pharmaceutical health insurance administrators, who allegedly favor more expensive insulin products and force patients to pay more.